Health and Healthcare
Why Marinus Pharmaceuticals Shares Are Sliding
Published:
Last Updated:
Shares of Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) tumbled Monday morning after the company gave an update on top-line results from its Phase 3 clinical trial in adults with drug-resistant focal onset seizures. Unfortunately, ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo.
Considering previous studies, ganaxolone was consistent in being generally safe and well tolerated. Marinus plans to discontinue its program in adult focal onset seizures and focus its efforts on advancing ganaxolone in status epilepticus and pediatric orphan indications.
Overall, management was disappointed with the outcome of this study, and the unfortunate impact on the epilepsy community and particularly the patients suffering from drug-resistant focal onset seizures who are benefiting from ganaxolone treatment. Yet, the company does remain confident in the safety profile of ganaxolone and its ability to effectively reduce seizures in targeted patient populations.
The company said that it will provide an update in the upcoming weeks on its clinical programs in these indications.
Dr. Albena Patroneva, chief medical officer of Marinus, added:
The design, conduct, patient demographics and median separation versus placebo were similar to our positive Phase 2 trial and other studies conducted with recently approved antiepileptic drugs. While we did not see the incremental efficacy at a higher dose that we were hoping to achieve, ganaxolone continued to display a good safety profile – a key attribute for the product’s future development. We will leverage the findings from this study in the conduct of our ongoing and future studies in pediatric orphan indications and status epilepticus.
Shares of Marinus were down 70.2% at $1.59 early Monday morning, with a consensus analyst price target of $14.60 and a previous 52-week trading range of $4.00 to $20.72.
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
